RECOMBINANT PLASMID DNA pGG-1 CODING POLYPEPTIDE OF HUMAN PROINSULIN GLARGIN AND STRAIN OF BACTERIA ESCHERICHIA COLI BGG18-PRODUCER OF RECOMBINANT PROINSULIN GLARGIN Russian patent published in 2008 - IPC C12N15/62 C12N15/17 C12N1/21 C12R1/19 

FIELD: organic chemistry, genetics.

SUBSTANCE: invention refers to genetic engineering, specifically to production of proinsulin Glargin and can be applied for production of medicines of new generation used for insulin-dependent pancreatic diabetes. Designed recombinant plasmid DNA pGG-1 codes hybrid protein with amino acid sequence of proinsulin Glargin, where sequence of domain B of protein A Staphylococcus aureus is connected through peptide linker His₆GlySerArg with amino acid sequence of proinsulin Glargin having molecular weight 3,3 MDa (5051 "п.о"), containing HindIII/BamHI-fragment of plasmide pPINS07, including hybride tac-promoter, gene of β-lactamase ("bla"), replication origin area (ori), terminator of ribosomal operon E. coli transcription, nucleotide sequence coding amino acid sequence of domain B of protein A Staphylococcus aureus, connected to nucleotide sequence coding peptide His₆GlySerArg, HindIII/BamHI-fragment (271 "п.о"), coding proinsulin Glargin; unique restriction sites with following coordinates: EcoRI - 1, NcoI - 217, BamHI - 221, PstI - 342 and 417, HindIII - 492, SalGI - 4513, ClaI - 4792. Bacteria Escherichia coli BL21 are transformed with plasmide pGG-1 that resulted in strains Escherichia coli BGG18, producer of hybride polypeptide containing amino acid sequence of proinsulin Glargin. Invention enables to produce insulin Glargin with high yield and applying simplified technology.

EFFECT: production of insulin Glargin with high yield and applying simplified technology.

2 cl, 4 dwg, 4 ex